Reporting of Thromboembolic Events with JAK Inhibitors: Analysis of the FAERS Database 2010-2019.

Drug Saf · 2021 · PMC8280037 · PMID 34120321

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

may be significantno p-value reported

Although data from clinical trials suggest the risk is low, they are limited by the relatively low number of patients in the pivotal studies and the exclusion of participants with a higher burden of comorbidities; however, findings from postmarketing studies suggest the risk may be significant [ 7 , 14 ].

also in 13,097 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.